Literature DB >> 30415499

Human Cardiac Organoids for Disease Modeling.

Bramasta Nugraha1, Michele F Buono1, Lisa von Boehmer1, Simon P Hoerstrup1,2, Maximilian Y Emmert1,2,3,4.   

Abstract

Human cardiac drug discovery and disease modeling face challenges in recapitulating cellular complexity and animal-to-human translation due to the limitations of conventional 2D cell culture and animal models. The development of human cardiac organoid technologies could help in stimulating and maintaining differentiated cell functions for extended periods of time. By closely mimicking in vivo organ functions in vitro they could thereby help in overcoming the obstacles mentioned above. Through the construction of human cardiac organoids from pluripotent stem cell-derived cells, derived from patients with specific known genotypes and phenotypes, more complex and robust in vitro tools have recently become available for disease modeling. In this review, we will describe the relevance and importance of evolving organoid platforms in disease biology. We further provide examples of cardiac organoid platforms, which may lead the way toward future personalized medicine and drug discovery.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2018        PMID: 30415499     DOI: 10.1002/cpt.1286

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

1.  Diffraction-based technology for the monitoring of contraction dynamics in 3D and 2D tissue models.

Authors:  Ronan Le Harzic; Ina Meiser; Julia C Neubauer; Iris Riemann; Michael Schiffer; Frank Stracke; Heiko Zimmermann
Journal:  Biomed Opt Express       Date:  2020-01-02       Impact factor: 3.732

Review 2.  Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.

Authors:  Emily A Pinheiro; Tarek Magdy; Paul W Burridge
Journal:  J Cardiovasc Transl Res       Date:  2020-02-20       Impact factor: 4.132

Review 3.  Myocardial infarction from a tissue engineering and regenerative medicine point of view: A comprehensive review on models and treatments.

Authors:  Gozde Basara; Gokhan Bahcecioglu; S Gulberk Ozcebe; Bradley W Ellis; George Ronan; Pinar Zorlutuna
Journal:  Biophys Rev (Melville)       Date:  2022-08-30

4.  Exploring the Potential of Symmetric Exon Deletion to Treat Non-Ischemic Dilated Cardiomyopathy by Removing Frameshift Mutations in TTN.

Authors:  Ignacio Rodriguez-Polo; Rüdiger Behr
Journal:  Genes (Basel)       Date:  2022-06-19       Impact factor: 4.141

Review 5.  The updated view on induced pluripotent stem cells for cardiovascular precision medicine.

Authors:  Yong Wang; Wei Lei; Jingsi Yang; Xuan Ni; Lingqun Ye; Zhenya Shen; Shijun Hu
Journal:  Pflugers Arch       Date:  2021-02-17       Impact factor: 3.657

6.  A resazurin-based, nondestructive assay for monitoring cell proliferation during a scaffold-based 3D culture process.

Authors:  Xianghui Gong; Zhuqing Liang; Yongxing Yang; Haifeng Liu; Jing Ji; Yubo Fan
Journal:  Regen Biomater       Date:  2020-03-11

Review 7.  The myriad possibility of kidney organoids.

Authors:  Pinyuan Tian; Rachel Lennon
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-05       Impact factor: 2.894

Review 8.  Organoids and Microphysiological Systems: New Tools for Ophthalmic Drug Discovery.

Authors:  Jing Bai; Chunming Wang
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

Review 9.  In vitro Assays and Imaging Methods for Drug Discovery for Cardiac Fibrosis.

Authors:  Giorgia Palano; Ariana Foinquinos; Erik Müllers
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

10.  Airway and Alveoli Organoids as Valuable Research Tools in COVID-19.

Authors:  Miriane de Oliveira; Maria T De Sibio; Felipe A S Costa; Marna E Sakalem
Journal:  ACS Biomater Sci Eng       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.